ALDEYRA THERAPEUTICS INC (ALDX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALDX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALDX | President and Chief Executive Officer | 54 | ["President and Chief Executive Officer since January 2012","served as Entrepreneur in Residence at Domain Associates, LLC","has served on the board of directors of biotechnology companies","holds a Ph.D. in pathology from Duke University","holds an M.D. from Duke University Medical School","holds an A.B. from Dartmouth College in Philosophy and Psychology"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Brady has served as our President and Chief Executive Officer since January of 2012 and as a member of our Board of Directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady has served on the board of directors of a number of private and publicly traded biotechnology companies, including Evoke Pharma, Inc. until December 2025 and F-star Therapeutics, Inc. until March 2023. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology. Dr. Brady s extensive knowledge of our business, as well as his years of experience in the biotechnology industry, including executive leadership in several biotechnology companies, contributed to our conclusion that he should serve as a director of our Company.